Oct
2026
Fiera Milano, Italy
Visit us
stand 2J95, API

Shijiazhuang Lonzeal Pharmac.Co. ltd

Exhibitor at CPHI Milan 2026
About Us

Shijiazhuang Lonzeal Pharmaceuticals Co., Ltd. was founded on December 30th 2006. Lonzeal’s current core business is research and development, production and sales of anti-AIDS and hepatitis B drugs. We are now one of the most competitive manufacturers of anti-retrovirus (ARV for HIV and HBV) drugs in China, with product registration at international drug authorities including WHOPQ, China, India, Russia, Brazil and South Africa.

Read more Show less
Products
Show more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    China
  • On CPHI since:
    2015
  • Employees:
    500 - 999
Company types
Pharmaceutical company
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 2J95, API

Products Featured at CPHI Milan 2026

  • Baloxavir Marboxil

    Product Baloxavir Marboxil

    Shijiazhuang Lonzeal Pharmaceuticals Co Ltd offers a wide range of products which includes Baloxavir Marboxil. Product not provided to where patent is still valid
  • Pregabalin

    Product Pregabalin

    Shijiazhuang Lonzeal Pharmaceuticals Co Ltd offers a wide range of products which includes Pregabalin.
  • Emtricitabine

    Product Emtricitabine

    Shijiazhuang Lonzeal Pharmaceuticals Co Ltd offers a wide range of products which includes Emtricitabine.
  • Lamivudine

    Product Lamivudine

    Shijiazhuang Lonzeal Pharmaceuticals Co Ltd offers a wide range of products which includes lamivudine. It belongs to antiviral drugs APIi category. APIplication: anti-viral drug substance. Contact us for more information.
  • Tenofovir Alafenamide Fumarate（TAF）

    Product Tenofovir Alafenamide Fumarate（TAF）

    Shijiazhuang Lonzeal Pharmaceuticals Co Ltd offers a wide range of products which includes TAF.  Product not provided to where patent is still valid